Cold treatment trial calls for participants

FIREBRICK Pharma is looking for volunteers to participate in paid clinical trials in researching a remedy for the common cold.

The trial will study the effects of nasal spray Nasodine with participants receiving either active treatment or a placebo.

Ballarat is among the first to test the medication, and Firebrick Pharma’s executive chairman Dr Peter Molloy said it presents the chance to be part of a potential medical breakthrough.

“We believe Nasodine will be a first-in-class nasal spray medicine in that it actually targets the viral cause of the common cold, where colds start, in the nose,” he said.

“Victorian residents can be among the first in the world to try Nasodine, which in previous clinical trials has been shown to be safe and well-tolerated.

“This trial seeks to confirm the efficacy of Nasodine as a treatment for the common cold.”

Nasodine uses the same active ingredient, povidone-iodine, as another one of Dr Molloy’s products, Betadine Sore Throat Gargle.

The trial will be delivered by Barwon Health’s Adrian Costa Clinical Trials Centre through UFS Dispensaries.

Participants will be required for one appointment, continuing nasal spray treatment independently for five days alongside two weeks of electronic reporting.

Those who’ve had cold symptoms for under 36 hours will be eligible to join the trial.

To register, visit bit.ly/3bxikPN.